Payment overview · 2025
General Payments
$393,996.28
514 reported records · 39 companies
Healthcare provider profile · identity verified
John Michael Hemphill, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology with Special Qualifications in Child Neurology · SAVANNAH, GA · NPI 1285672329
Verified facts
What the public records show
CMS Open Payments records show John Michael Hemphill, M.D. received $393,996.28 in general payments during 2025 across 514 reported records.
Eisai Inc. accounted for 32.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Epidiolex, Fycompa, Mavenclad, Nurtec Odt, Qulipta, Qutenza, Rexulti, Ubrelvy, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ubrelvy by this doctor in 2024.
Averitas Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUTENZA as an associated drug or biological on 11743 records involving 7078 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qutenza by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Vumerity by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Fycompa by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Mavenclad as an associated drug or biological on 3542 records involving 766 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mavenclad by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Epidiolex by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xcopri by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $128,206.08 | 32.5% | 123 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49,673.31 | 12.6% | 54 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41,655.37 | 10.6% | 37 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33,379.36 | 8.5% | 29 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $33,082.14 | 8.4% | 16 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $27,140.10 | 6.9% | 32 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $26,168.15 | 6.6% | 24 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20,727.20 | 5.3% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18,909.93 | 4.8% | 45 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $6,800.76 | 1.7% | 12 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $4,841.74 | 1.2% | 9 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $1,029.39 | 0.3% | 10 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $361.80 | 0.1% | 15 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $180.61 | 0.1% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $176.35 | 0.0% | 9 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $158.33 | 0.0% | 8 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$135.51 | 0.0% | 8 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $122.67 | 0.0% | 7 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$113.25 | 0.0% | 5 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $111.87 | 0.0% | 5 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $105.22 | 0.0% | 5 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $86.59 | 0.0% | 4 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $76.11 | 0.0% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $75.80 | 0.0% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $74.64 | 0.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $73.51 | 0.0% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $73.26 | 0.0% | 4 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $72.12 | 0.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.35 | 0.0% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $53.36 | 0.0% | 2 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $52.88 | 0.0% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $44.52 | 0.0% | 2 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $37.84 | 0.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.82 | 0.0% | 1 | 2025 |
| Immedica Pharma US, Inc. | Unresolved — no canonical attribution shown | $24.76 | 0.0% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $22.67 | 0.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $21.46 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.88 | 0.0% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $14.57 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $206,128.25 | 67 |
| Compensation for serving as faculty or as a speaker for a medical education program | $88,963.75 | 50 |
| Travel and Lodging | $62,834.59 | 120 |
| Consulting Fee | $25,702.50 | 10 |
| Food and Beverage | $10,239.56 | 265 |
| Education | $127.63 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $128,247.53 | 125 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $41,524.72 | 36 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $33,379.36 | 29 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $25,230.79 | 12 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $24,819.99 | 25 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $18,854.33 | 26 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $18,488.89 | 26 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $11,549.83 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $6,767.07 | 10 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $4,841.74 | 9 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $1,382.61 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $390.28 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $379.83 | 15 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $158.33 | 8 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $147.14 | 6 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $137.72 | 6 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $134.95 | 7 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $122.67 | 7 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $113.25 | 5 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $111.87 | 5 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $86.59 | 4 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $76.11 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $75.80 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $74.64 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $73.51 | 4 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $73.26 | 4 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $72.12 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $69.35 | 4 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $63.77 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $53.36 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $46.85 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $44.52 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $42.08 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $41.40 | 2 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $37.84 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $34.83 | 3 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $33.69 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $30.09 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech, Inc. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| ZTALMY Normalized: ztalmy |
Drug | Immedica Pharma US, Inc. | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $11.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 86 | exact normalized | Medicare Part D |
| EPIDIOLEX epidiolex |
2025 | Epidiolex | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Mavenclad mavenclad |
2025 | Mavenclad | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 96 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 68 | exact normalized | Medicare Part D |
| QUTENZA qutenza |
2025 | Qutenza | 2024 | 16 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 70 | exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
70 | 22 |
| Averitas Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | QUTENZA open payments reported associated product |
CMS Open Payments — General Payments 11743 supporting records · 7078 recipient NPIs · example record 1248543069 |
Qutenza · 2024 Exact normalized brand match · 1 Part D row |
16 | 11 |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Mavenclad open payments reported associated product |
CMS Open Payments — General Payments 3542 supporting records · 766 recipient NPIs · example record 1236867010 |
Mavenclad · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
96 | 24 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
86 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 360 | 81 |
| Gabapentin | Gabapentin | 305 | 80 |
| Topiramate | Topiramate | 271 | 62 |
| Baclofen | Baclofen | 256 | 57 |
| Donepezil Hcl | Donepezil Hcl | 233 | 60 |
| Tizanidine Hcl | Tizanidine Hcl | 196 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 155 | 32 |
| Aimovig Autoinjector | Erenumab-Aooe | 140 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 138 | 29 |
| Sumatriptan Succinate | Sumatriptan Succinate | 125 | 29 |
| Lacosamide | Lacosamide | 122 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 118 | 30 |
| Lamotrigine | Lamotrigine | 116 | 25 |
| Propranolol Hcl Er | Propranolol Hcl | 113 | 30 |
| Rizatriptan | Rizatriptan Benzoate | 107 | 31 |
| Nurtec Odt | Rimegepant Sulfate | 96 | 24 |
| Memantine Hcl | Memantine Hcl | 92 | 24 |
| Primidone | Primidone | 92 | 20 |
| Clonazepam | Clonazepam | 87 | 14 |
| Briviact | Brivaracetam | 86 | 11 |
| Diazepam | Diazepam | 83 | 48 |
| Dalfampridine Er | Dalfampridine | 82 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 15 |
| Vumerity | Diroximel Fumarate | 72 | suppressed |
| Ubrelvy | Ubrogepant | 70 | 22 |
| Qulipta | Atogepant | 68 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 19 |
| Oxcarbazepine | Oxcarbazepine | 64 | 15 |
| Pregabalin | Pregabalin | 62 | 20 |
| Sertraline Hcl | Sertraline Hcl | 62 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 59 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 14 |
| Amantadine | Amantadine Hcl | 46 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 44 | suppressed |
| Carbamazepine | Carbamazepine | 41 | 11 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Fycompa | Perampanel | 39 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 35 | suppressed |
| Lamotrigine Er | Lamotrigine | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Teriflunomide | Teriflunomide | 28 | suppressed |
| Xcopri | Cenobamate | 27 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 26 | suppressed |
| Levetiracetam Er | Levetiracetam | 26 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Topiramate Er | Topiramate | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 23 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Austedo | Deutetrabenazine | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Promethazine Hcl | Promethazine Hcl | 21 | 11 |
| Eletriptan Hbr | Eletriptan Hydrobromide | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Riluzole | Riluzole | 19 | suppressed |
| Zonisamide | Zonisamide | 19 | suppressed |
| Clobazam | Clobazam | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Kesimpta Pen | Ofatumumab | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Qutenza | Capsaicin/Skin Cleanser | 16 | 11 |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Felbamate | Felbamate | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 12 | suppressed |
| Almotriptan Malate | Almotriptan Malate | 11 | suppressed |
| Lamictal | Lamotrigine | 11 | suppressed |
| Mavenclad | Cladribine | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 11 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $393,996.28 · 514 records | Eisai Inc. | ACTHAR, AUSTEDO XR, BOTOX, BRIUMVI, Briviact, DAXXIFY, DAYBUE, Dysport, EPIDIOLEX, FYCOMPA, Fintepla, Gamunex-C, Hizentra, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, Mavenclad, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, QUTENZA, REXULTI, Rystiggo, Symbravo, TRUDHESA, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, Xeomin, ZAVZPRET, ZEPOSIA, ZTALMY, ZTLido | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error